Physician profile
Namrata Kumar
NPI 1407910896
$22,511.35
in general payments reported to CMS, 2019-2025
40 companies · $2,470 in 2025
The $2,470 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12K · 2022: $2,663 · 2023: $2,350 · 2024: $2,618 · 2025: $2,470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,363 · Education: $75.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,362.91 |
| Education | $75.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zealand Pharma US, INC. | $9,928.49 | 2021-2022 | |
| Mannkind Corporation | $2,602.14 | 2021-2025 | Afrezza |
| Novo Nordisk INC | $1,496.62 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $1,422.76 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $982.40 | 2022-2025 | Korlym |
| Dexcom, INC. | $653.69 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $639.10 | 2021-2025 | Mounjaro, Zepbound, Humulin |
| Sanofi-Aventis U.S. LLC | $525.62 | 2021-2025 | |
| Amgen INC. | $452.53 | 2024-2025 | Tepezza |
| Ascendis Pharma Endocrinology INC | $395.75 | 2024-2025 | Yorvipath |
| Bayer Healthcare Pharmaceuticals INC. | $339.17 | 2021-2025 | |
| Abbott Laboratories | $328.44 | 2021-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $310.25 | 2021-2023 | Steglatro, Steglujan |
| Medtronic, INC. | $294.12 | 2022-2024 | Minimed 780g |
| Ascensia Diabetes Care US INC. | $261.38 | 2021-2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Namrata Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.